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Unlike traditional anticoagulants, the more recently developed agents rivaroxaban, dabigatran and apixaban target
specific factors in the coagulation cascade to attenuate thrombosis. Rivaroxaban and apixaban directly inhibit Factor
Xa, whereas dabigatran directly inhibits thrombin. All three drugs exhibit predictable pharmacokinetic and
pharmacodynamic characteristics that allow for fixed oral doses in a variety of settings. The population
pharmacokinetics of rivaroxaban, and also dabigatran, have been evaluated in a series of models using patient data
from phase II and III clinical studies. These models point towards a consistent pharmacokinetic and
pharmacodynamic profile, even when extreme demographic factors are taken into account, meaning that doses
rarely need to be adjusted. The exception is in certain patients with renal impairment, for whom pharmacokinetic
modelling provided the rationale for reduced doses as part of some regimens. Although not routinely required, the
ability to measure plasma concentrations of these agents could be advantageous in emergency situations, such as
overdose. Specific pharmacokinetic and pharmacodynamic characteristics must be taken into account when
selecting an appropriate assay for monitoring. The anti-Factor Xa chromogenic assays now available are likely to
provide the most appropriate means of determining plasma concentrations of rivaroxaban and apixaban, and
specific assays for dabigatran are in development.
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In recent years, the scope for effective management of
venous and arterial thromboembolic diseases has been
enhanced by the advent of novel oral anticoagulants
(OACs) that, unlike traditional oral vitamin K antago-
nists (VKAs) [1], are given at fixed doses and have a
lower potential for drug and food interactions [2]. These
agents show similar or improved efficacy and safety profiles
compared with VKAs, such as warfarin, and established
parenteral agents, including unfractionated heparin and
low molecular weight heparin [2].
The currently licensed novel OACs are rivaroxaban
(XareltoW, Bayer Pharma AG and Janssen Pharmaceuti-
cals, Inc.), dabigatran (PradaxaW, Boehringer Ingelheim* Correspondence: wolfgang.mueck@bayer.com
Bayer Pharma AG, Clinical Pharmacology, D-42096 Wuppertal, Germany
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reproduction in any medium, provided the orInternational GmbH) and apixaban (EliquisW, Bristol-
Myers Squibb and Pfizer EEIG). All three of these
agents, and others in development, are under investiga-
tion for the management of multiple thromboembolic
disorders. Rivaroxaban, a direct Factor Xa inhibitor, is
now approved in the European Union (EU), United
States (US) and elsewhere for the prevention of venous
thromboembolism (VTE) in adults who have undergone
elective hip or knee replacement surgery at a dose of
10 mg once daily (od) given for 2 weeks (knee) or
5 weeks (hip) [3,4]. Apixaban [5], another direct Factor
Xa inhibitor, and dabigatran [6], a direct thrombin in-
hibitor, are now also approved in the EU for the same
orthopaedic indication. In addition, rivaroxaban is ap-
proved for the prevention of stroke and systemic embol-
ism in adults with non-valvular atrial fibrillation (AF)
(20 mg od; EU and US) [3,4], and for the treatment ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(PE), and prevention of recurrent DVT and PE in adult
patients (15 mg twice daily [bid] for 3 weeks followed by
20 mg od; EU and US) [3,4]. Apixaban and dabigatran
are also licensed to reduce the risk of stroke and
systemic embolism in patients with non-valvular AF in
Europe and the US [5-8]. Rivaroxaban has also recently
been approved in the EU for the secondary prevention
of acute coronary syndrome (ACS); rivaroxaban admin-
istered with acetylsalicylic acid (ASA) alone or with ASA
plus clopidogrel or ticlopidine is indicated for the pre-
vention of atherothrombotic events in adult patients
with elevated cardiac biomarkers after ACS [3].
The novel OACs have mechanisms of action that at-
tenuate thrombotic processes via direct targeting of spe-
cific factors in the coagulation cascade [9]. An essential
component of the clinical development of these agents
has been a full characterisation of their pharmacokinetic
(PK) and pharmacodynamic (PD) profiles. In particular,
the phase III clinical trial programme for rivaroxaban
has been supported by a comprehensive set of phase I
and II studies evaluating PK and PD in both healthy sub-
jects and patients receiving the drug for active preven-
tion or treatment of thrombosis [10-12]. These studies
have demonstrated the predictable PK and PD properties
of rivaroxaban that allow fixed oral dosing regimens to
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Figure 1 The coagulation cascade and targets of anticoagulant agent
unfractionated heparin; VKA, vitamin K antagonist [9].aspects, such as limited clinically relevant drug–drug in-
teractions [10].
Because of their predictable PK/PD profiles, rivaroxaban
and other novel OACs do not require routine coagulation
monitoring [2]. However, there are circumstances in which
it may be necessary or desirable to measure their anti-
coagulant effect or the plasma levels of these drugs [9]. In
such cases, it is important to appreciate the PK properties
of the drugs and their influence on coagulation assays. The
objectives of this review are to provide an overview of the
mechanism of action of rivaroxaban, to summarise its
known PK and PD characteristics in healthy subjects and
patient populations, and to give information on potential
laboratory tests for rivaroxaban. Dabigatran and apixaban
are discussed where relevant differences exist.
Mechanism of action of novel oral anticoagulants
Unlike traditional anticoagulant agents, the VKAs and
heparins, novel OACs have been designed to inhibit spe-
cific single targets in the coagulation cascade (Figure 1)
[9]. Rivaroxaban and apixaban directly inhibit Factor Xa,
whereas dabigatran targets thrombin (Factor IIa). In
addition, the parenteral agent fondaparinux indirectly in-
hibits Factor Xa (Figure 1).
Rivaroxaban, the first oral, direct Factor Xa inhibitor to
be developed, was designed to specifically target Factor Xa













s. LMWH, low molecular weight heparin; TF, tissue factor; UFH,
Mueck et al. Thrombosis Journal 2013, 11:10 Page 3 of 17
http://www.thrombosisjournal.com/content/11/1/10between the intrinsic and extrinsic pathways in the coagu-
lation process [13] and is responsible for converting pro-
thrombin (Factor II) to thrombin (Factor IIa) [14]. In
preclinical studies, rivaroxaban was found to be highly se-
lective for Factor Xa, with an inhibitory effect >10,000 fold
higher than for related serine proteases and an inhibition
constant (Ki) of 0.4 nmol/l [10]. Importantly, rivaroxaban
was shown to inhibit free, prothrombinase-associated and
clot-associated Factor Xa without having a direct effect on
platelet aggregation [15]. This is in contrast to the indirect
Factor Xa inhibitors, such as fondaparinux, which do not
inhibit Factor Xa that is bound to the prothrombinase
complex [16]. Unlike rivaroxaban, fondaparinux also re-
quires an antithrombin cofactor [9]. Because rivaroxaban
does not inhibit thrombin directly, rivaroxaban does not
affect the haemostatic function of pre-existing thrombin
molecules [16].
Given the central role of thrombin in coagulation, dir-
ect targeting of this factor results in an antithrombotic
effect. Thrombin is produced in small amounts in the
initiation phase of the coagulation cascade but is gener-
ated in much greater amounts in the propagation phase
and is essential to the amplification of coagulation and
the formation of fibrin [14].
Pharmacokinetic and pharmacodynamic
properties of rivaroxaban and other novel oral
anticoagulants in healthy volunteers and specific
patient populations
Phase I studies in healthy volunteers and special
populations
In phase I studies in healthy subjects, rivaroxaban was
found to have predictable PK properties (Table 1), with
high absolute bioavailability after oral dosing [10,17], high
and reversible plasma protein binding and a mean terminal
half-life of 5–13 hours after a 10 mg dose [3,18]. Systemic
clearance was low (approximately 10 l/h) [3]. Unchanged
rivaroxaban was the predominant compound found in hu-
man plasma, and no major or active circulating metabolites
were detected [19]. After single doses of 1.25–80 mg,
which were well tolerated and did not lead to an increasedTable 1 Pharmacokinetic parameters (median values) of rivar
Agent Fabs, % Cmax, ng/ml AUC, ng · h/ml tmax, h t½
Rivaroxaban 80–100 [3] 141* [17] 1020* [17] 2–4 [3] 5–1
Apixaban 50 [5] 460† [23] 4100† [23] 3–4 [5] 12
Dabigatran 6.5 [6] 110‡ [24] 900‡ [24] 1–2 [6] 12–
*With 10 mg oral dose.
†With 20 mg oral dose.
‡With 150 mg oral dose.
Values rounded to nearest integer.
AUC area under the concentration–time curve, CL/F apparent clearance, Cmax maxim
concentration, t½ apparent half-life, Vd volume of distribution at steady state.risk of bleeding, peak plasma concentrations occurred
within 2–4 hours of dosing, and maximal Factor Xa inhib-
ition was seen after 1–4 hours [17]. This fast onset of ac-
tion is similar to that of the low molecular weight heparins;
for enoxaparin, maximum plasma anti-Factor Xa activity
occurs 1–4 hours after injection [20]. The half-life of the
biological effect of rivaroxaban was 6–7 hours, with Factor
Xa inhibition still evident 24 hours after the administration
of doses >5 mg [17]. Rivaroxaban was selective for Factor
Xa inhibition and had no direct effect on thrombin and no
effect on antithrombin activity [17]. When multiple doses
up to 30 mg bid were given for 7 days, Factor Xa activity
was inhibited in a dose-dependent manner, reaching a
maximum after approximately 3 hours and continuing for
at least 12 hours [21]. Peak plasma concentrations were
reached after 3–4 hours and the terminal half-life was 5.7–
9.2 hours at steady state, without accumulation at any dose
[21]. The systemic clearance and volume of distribution in
healthy volunteers are approximately 10 l/h and 50 litres,
respectively, with moderate interindividual variability [3].
For single and multiple doses, prolongation of coagulation
tests followed a similar profile to Factor Xa inhibition and
correlated closely with plasma concentrations [22].
Several phase I studies were also conducted in special
patient populations. These indicated that relevant PK
and PD parameters remained consistent regardless of
body weight [26], age [27,28], gender [28,29] or ethnicity
[29,30], suggesting that dose adjustment is unnecessary.
However, the presence of hepatic and renal impairment
may lead to relevant PK/PD effects. For a 10 mg dose,
mild hepatic impairment (Child–Pugh A) led to minimal
PK and no PD changes compared with healthy controls,
although moderate impairment (Child–Pugh B) led to
significant increases in exposure and associated en-
hanced Factor Xa inhibition [3,31]; there are no data in
patients with severe hepatic impairment. Approximately
two-thirds of a rivaroxaban dose undergoes metabolic
degradation, of which half is eliminated renally and half
via the hepatobiliary route; the other one-third of the ad-
ministered dose is excreted directly via the kidneys as
unchanged, active drug, principally through active renaloxaban, apixaban and dabigatran in healthy adults
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(P-gp) and breast cancer resistance protein [3,19]. This
gives an overall renal clearance of 3–4 l/h, meaning that de-
creasing renal function leads to an increase in rivaroxaban
plasma concentrations and, correspondingly, PD effects
[32]. No data exist for patients with creatinine clearance
(CrCl) min/min. As a result of high plasma protein binding
(92–95% [3,18]), rivaroxaban is not expected to be
dialysable [3].
Taking rivaroxaban with food did not have a signifi-
cant effect on PK parameters for a 10 mg dose com-
pared with fasting [3], but decreases in maximum
plasma concentration (Cmax) and overall exposure (area
under the concentration–time curve, AUC) were evident
at a dose of 20 mg in the fasted state [33], as a result of
decreased bioavailability and absorption rate with in-
creasing dose [22]. When a dose of 20 mg was adminis-
tered with food, complete bioavailability of rivaroxaban
was restored [34]. Absorption was not affected by
changes in gastric pH induced by ranitidine or antacid
[33]. Because rivaroxaban is metabolised via cytochrome
P450 (CYP) 3A4, CYP2J2 and CYP-independent mecha-
nisms, and active renal secretion is mediated by P-gp
and breast cancer resistance protein, co-administration
with strong inhibitors of both CYP3A4 and P-gp, such
as the azole antimycotic ketoconazole or the HIV prote-
ase inhibitor ritonavir, led to increased exposure and PD
effects [3,35]. Strong inhibitors of one or the other, or
moderate inhibitors of both of these pathways produced
less marked effects [3,35]. Concomitant administration
of rivaroxaban and strong CYP3A4 and P-gp inducers,
such as the antibiotic rifampicin, led to decreases in PK
and PD effects, whereas interactions with substrates of
CYP3A4 and/or P-gp were considered not to be clinically
relevant. Rivaroxaban does not inhibit or induce any major
CYP isoforms, such as CYP3A4 [3]. Co-administration with
enoxaparin produced an additive PD effect but did not
affect the PK of rivaroxaban [3,36]. Clopidogrel did not
affect rivaroxaban PK but did lead to a relevant increase in
bleeding time in approximately one-third of healthy sub-
jects, although this was not correlated with changes in
platelet aggregation [37]. Co-medication with naproxen or
ASA did not lead to clinically relevant prolongation of
bleeding time overall [38], but some individuals exhibited
pronounced PD effects with rivaroxaban plus ASA [39].
Apixaban and dabigatran exhibit broadly similar PK pro-
files to rivaroxaban, but with some notable exceptions
(Table 1). Unlike apixaban and rivaroxaban, dabigatran is
administered as a prodrug (dabigatran etexilate). The latter
is a substrate of P-gp and its low oral bioavailability is deter-
mined by intestinal P-gp transporters [40]. Once absorbed,
the prodrug is rapidly converted to dabigatran by esterases
[40]. The volume of distribution of apixaban [5] is lower
than that of rivaroxaban [3] and dabigatran [6], which inturn exhibit higher clearance and lower protein binding.
An important difference between the drugs is also the pro-
portion of each that is excreted via the kidneys; renal elim-
ination of apixaban (approximately 27%; the majority is
excreted via the hepatobiliary route) [5] is slightly lower
than that of rivaroxaban [3], but that of dabigatran is con-
siderably higher (85%) [25]. Unlike rivaroxaban [3] and
apixaban [5], neither dabigatran nor its prodrug are
metabolised by CYP-dependent mechanisms [6]; however,
owing to dabigatran etexilate being a P-gp substrate, the ef-
fect of P-gp inhibitors on the bioavailability of dabigatran is
stronger than on rivaroxaban elimination [6].
Venous thromboembolism prevention in the orthopaedic
setting
All three approved novel OACs underwent initial clinical
evaluation for the prevention of VTE after elective hip or
knee replacement surgery. This population experiences high
levels of post-operative VTE in the absence of adequate
thromboprophylaxis [41]. The rivaroxaban phase III clinical
programme comprised four studies, RECORD1 [42], REC-
ORD2 [43], RECORD3 [44] and RECORD4 [45], in more
than 12,500 patients undergoing elective total hip replace-
ment (THR) or total knee replacement (TKR). All four trials
showed a significant efficacy benefit with rivaroxaban over
the comparator enoxaparin regimens without an increase in
major bleeding, and this was confirmed by pooled analyses
[46,47]. The preceding phase II clinical trials (ODIXa-HIP
[48], ODIXa-HIP2 [49], ODIXa-KNEE [50] and ODIXa-
HIP-OD [51]) of rivaroxaban for VTE prevention in patients
undergoing THR or TKR collected data that were used to
construct population PK/PD models to characterise the PK
and PD properties of rivaroxaban in orthopaedic surgery
populations [11,52]. One model compared rivaroxaban od
and bid doses in patients undergoing THR and investigated
the influence of patient demographic characteristics on PK
and PD parameters [11]. Only doses that had demonstrated
a favourable profile compared with enoxaparin, i.e. total
daily doses of 5–20 mg, were considered. The other model
included both THR and TKR patients from the phase II
programme [52]. In both models, PK data were fed into a
non-linear mixed effects model (NONMEM), which al-
lows population estimates to be derived for PK and PK/
PD parameters and quantifies both the interindividual and
interoccasion variability of these parameters, as well as re-
sidual (unexplained) variability. Importantly, inputs to the
model could then be modified to simulate the effect of dif-
ferent dosing regimens and population demographic fac-
tors (such as age, renal function and body weight) and the
effect of co-medications [11,52].
In the first model described above, a total of 5743 sam-
ples from 758 patients (362 patients from the bid study and
396 patients from the od study) were included. Patient
demographics were similar between the rivaroxaban od and
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concentrations (mean, 5/95 percentiles) are shown in
Table 2. An oral, one-compartment model with a first-
order rate constant was found to accurately describe the
PK of rivaroxaban. The results of the model confirmed that
rivaroxaban exhibited a predictable, dose-proportional PK
profile in THR patients, as it had in healthy volunteers, with
similar values for PK parameters (Table 3). The maximum
plasma concentration (Cmax) for a 10 mg od dose was simi-
lar to that in healthy volunteers (median 125 ng/ml vs
141 ng/ml). Steady-state trough concentrations (Ctrough)
were a median of approximately 9 ng/ml; this value was in
the order of magnitude required for in vitro inhibition of
Factor Xa activity, which supported the use of the
rivaroxaban 10 mg od dose [11]. PK parameters were af-
fected by body weight, study day, age, renal function, serum
albumin and haematocrit, but the average of these effects
remained within the overall variability of the population.
The residual variability of the model was moderate
(52.6%). PK/PD analysis of both the rivaroxaban od and
bid data indicated that prolongation of prothrombin time
(PT), measured using the STAW NeoplastineW CI Plus
assay (Diagnostica Stago, Parsippany, NJ, USA), correlated
strongly with rivaroxaban plasma concentrations [11].
In order to provide insight into the expected influence of
patient demographics, the model was then used to simulate
the PK of rivaroxaban 10 mg od in patients with extreme
characteristics; this included age 90 years, moderate to se-
vere renal impairment (creatinine clearance [CrCl] 30 ml/
min), low body weight (40 kg) and combined age 90 years
and low body weight. The predicted plasma concentra-
tion–time profiles of rivaroxaban for the typical individual
in each of the four demographic groups fell within the pre-
dicted 90% confidence intervals for the average population
in these studies (Figure 2), confirming that rivaroxaban
10 mg od could be given without the need for dose adjust-
ment in THR patients regardless of factors such as old age
and moderate renal impairment [11]. In the second model,
the only major difference between PK properties for TKR
and THR was that clearance was 26% lower in the knee
study, which led to ~30% greater exposure. The models
exhibited moderate residual variability (37% and 34% in
the hip and knee studies, respectively) [52].
In its phase III clinical programme, dabigatran 150 mg
and/or 220 mg od were compared with enoxaparin regi-
mens for the prevention of total VTE in patients who had
undergone TKR (RE-MODEL [53] and RE-MOBILIZE [54]
trials) or THR (RE-NOVATE [55] and RENOVATE II [56]
studies). As with rivaroxaban, the doses used in these phase
III trials were determined by a series of phase II studies,
and one of these (BISTRO I) also provided PK data that
could be used to construct a population PK model [57]. In
total, 289 patients received dabigatran at doses of 150 or
300 mg od or 12.5–300 mg bid, and 4604 blood sampleswere available for use in the model [57]. Unlike for
rivaroxaban, a two-compartment model most accurately
described the PK profile of dabigatran, which demonstrated
dose-proportionality and linear kinetics. The rate of drug
absorption and apparent clearance during days 0 and 1 of
treatment were significantly lower (p < 0.001) than on days
2–10, which may be explained by changes in gastrointes-
tinal motility caused by surgical effects or co-medication; a
similar finding was reported in the rivaroxaban models for
this patient population. Weight, gender, variations in most
laboratory measurements, smoking and alcohol consump-
tion did not affect the PK of dabigatran but, unsurprisingly
for a drug with 80% renal clearance, decreasing CrCl sig-
nificantly increased plasma exposure [57]. Despite this,
simulations indicated an apparent degree of overlap in con-
centration–time profiles for renally impaired patients com-
pared with unimpaired controls, supporting the use of
fixed dabigatran doses in patients undergoing THR regard-
less of demographic factors [57].
The phase III programme investigating apixaban for VTE
prophylaxis after THR or TKR surgery consisted of three
studies, ADVANCE-1, ADVANCE-2 and ADVANCE-3
[58-60], which compared apixaban 2.5 mg bid with stand-
ard enoxaparin regimens. No population PK model for
apixaban in the orthopaedic setting has yet been published.
Treatment of acute deep vein thrombosis and prevention
of recurrent venous thromboembolism
VTE is a major global healthcare problem that carries a
substantial morbidity and mortality burden in the gen-
eral population [61,62]. The phase III EINSTEIN DVT
[63] and EINSTEIN PE [64] studies assessed a single-
drug approach using rivaroxaban against the standard
dual-drug approach of enoxaparin overlapping with a
VKA in patients with confirmed acute symptomatic
DVT or PE. These studies found that rivaroxaban was as
effective as this standard regimen with similar or better
safety outcomes. An extension study (EINSTEIN EXT)
indicated that long-term rivaroxaban was also more ef-
fective than placebo in preventing recurrent VTE [63].
Given that high rates of VTE recurrence in the acute
phase of treatment were seen in previous studies [65,66],
a higher dose of rivaroxaban (15 mg bid) was employed
in the first 3 weeks of treatment. The basis for the
chosen regimen (15 mg bid for 3 weeks followed by
20 mg od) stemmed from the outcomes from two phase
II studies (EINSTEIN and ODIXa-DVT) [67,68], which
demonstrated a greater reduction in thrombosis burden
with bid compared with od dosing in the acute phase of
treatment. These studies also collected PK data to pro-
duce a population model to characterise the PK/PD of
rivaroxaban od and bid doses in patients with acute
DVT, including evaluation of the influence of demo-
graphic factors.
Table 2 Concentration–time profiles for rivaroxaban in different patient populations observed in clinical studies [Bayer HealthCare Pharmaceuticals and




VTE prevention: DVT treatment: Prevention of stroke in patients with AF
and CrCl ≥50 ml/min:
Prevention of stroke in patients with AF
and CrCl <50 ml/min:
Prevention of CV events in
patients with ACS:
10 mg od 15 mg bid for 3 weeks
followed by 20 mg od













1 111 (75.1–177) 235 (164–361) 216 (152–316) 189 (134–281) 41.3 (23.5–65.9)
2 122 (90.6–195) 270 (189–419) 250 (177–361) 219 (157–317) 44.1 (26.7–69.5)
3 114 (82.3–186) 259 (180–405) 246 (172–361) 216 (153–317) 42.0 (25.9–66.4)
4 102 (75.8–164) 237 (161–369) 232 (157–349) 205 (141–309) 38.7 (23.3–63.3)
5 90.7 (62.2–143) 213 (145–339) 215 (140–333) 191 (127–297) 35.2 (20.2–59.1)
6 80.2 (51.8–125) 191 (123–311) 198 (123–318) 177 (111–286) 31.7 (17.4–55.5)
9 55.2 (30.5–96.0) 137 (71.3–240) 155 (81.9–276) 141 (74.9–254) 22.8 (10.4–45.2)
12 37.8 (15.2–76.1) 97.8 (42.9–190) 121 (53.4–242) 112 (50.0–225) 16.2 (6.11–36.6)
18 17.9 (4.85–49.9) 50.0 (16.0–124) 73.5 (22.0–187) 70.4 (21.9–180) −
24 8.54 (1.36–37.2) 25.6 (5.93–86.9) 44.7 (9.02–147) 44.4 (9.42–143) −
Plasma concentrations given as geometric mean values with 90% prediction intervals (5/95 percentiles). Values given to 3 significant figures.

















Table 3 Comparison of selected pharmacokinetic parameters (median values) with rivaroxaban in specific patient populations
Population and rivaroxaban dose Cmax, ng/ml Ctrough,
ng/ml
AUC, ng · h/ml Vd/F, l Interindividual
variability in Vd, %CV
CL/F, l/h Interindividual
variability in CL/F, %CV
Hip surgery patients, 2.5–10 mg bid; 10 mg od 125* [11] 9* [11] 1170† [11] 58 [11] 32 [11] 5–8 [11] 38 [11]
Patients treated for DVT; 10 mg bid, 20 and
30 mg od or bid, or 40 mg od
270 [12] 25‡ [12] 2870 [12] 54 [12] 29 [12] 6 [12] 40 [12]
Patients with AF; 15 and 20 mg od 257‡ [Girgis.
Unpublished data]











Patients with ACS; 2.5 mg bid 44§ [86] 16§ [86] 361§ [86] 58 [86] 10 [86] 6.5 [86] 31 [86]
*10 mg od.
†AUC over a 24-hour period at steady-state.
‡20 mg od at steady-state.
§2.5 mg bid at steady-state; AUC over a 12-hour period.
Values rounded to nearest integer.
AF atrial fibrillation, AUC area under the concentration–time curve, bid twice daily, Cmax maximum plasma concentration, Ctrough steady-state trough concentration, CL/F apparent clearance, CV coefficient of variance,

















Figure 2 Simulations of rivaroxaban plasma concentration–time profiles in typical patients compared with overall population
estimates. Typical patients are elderly (90 years), have moderate to severe renal impairment; CrCl 30 ml/min), have low body weight (40 kg), or are
elderly with low body weight. Patients receiving rivaroxaban 10 mg once daily (mean with 90% interval) [11]. CrCL/CrCl, creatinine clearance.
Reproduced with permission from Mueck W, Borris LC, Dahl OE et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily



























Typical patient aged 60 years, weighing 80 kg, CLCR 90 mL/min 
5th and 95th percentiles
Patient aged 90 years, CLCR ~30 mL/min
Patient with CLCR~35 mL/min 
Patient aged 90 years, weighing ~45 kg
Patient aged 90 years
Patient weighing ~45 kg
Time after administration (hours)
Figure 3 Predicted plasma rivaroxaban concentration–time
profiles for extremes in age, renal function and body weight.
Patients receiving rivaroxaban 20 mg once daily. The simulated
patients had typical mean characteristics (age 60 years, body weight 80
kg, CrCl 90 ml/min) unless specified otherwise [12]. CLCR/CrCl,
creatinine clearance. Reproduced from Mueck W, Lensing AW, Agnelli
G et al. Rivaroxaban: population pharmacokinetic analyses in patients
treated for acute deep-vein thrombosis and exposure simulations in
patients with atrial fibrillation treated for stroke prevention. Clin
Pharmacokinet 2011; 50:675–686 with permission from Adis (© Springer
International Publishing AG 2011. All rights reserved).
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plasma samples from 870 patients [12]. Observed
rivaroxaban plasma concentrations (mean, 5/95 percen-
tiles) are shown in Table 2. As for healthy subjects and pa-
tients who had undergone major orthopaedic surgery,
rivaroxaban PK was well described by a one-compartment
model. Median Cmax, Ctrough and AUC values at steady
state at the daily dose chosen for the phase III programme
(20 mg od) were correspondingly higher than for a 10 mg
od dose (Table 3), and rivaroxaban exhibited the same pre-
viously documented dose-proportional PK profile. Age and
renal function moderately affected the PK profile, but vari-
ations were within the overall variability seen in the studies
(Figure 3) [12]. Variations in gender and body weight had a
minimal effect. Simulations of the approved rivaroxaban
dosing regimen for VTE treatment (15 mg bid for 3 weeks
followed by 20 mg od) demonstrated that no fluctuations
in Cmax would be expected during the transition from bid
to od dosing (Figure 4). Co-administration of laxatives, di-
uretics, non-steroidal anti-inflammatory drugs and ASA
did not significantly alter the PK profile of rivaroxaban, al-
though use of concomitant strong CYP3A4 inducers re-
duced rivaroxaban exposure by up to 50% [12]. As seen for
patients undergoing orthopaedic surgery, an almost linear
correlation between rivaroxaban exposure and PT pro-
longation was demonstrated [12].
Dabigatran has been evaluated for the treatment of
acute VTE in the RE-COVER and RE-COVER II clinical
trials [69,70]. In these studies, patients received either
parenteral anticoagulant followed by dabigatran 150 mg
Study day





























5th and 95th percentiles
Figure 4 Simulated venous thromboembolism treatment dosing regimen of rivaroxaban. Regimen is 15 mg bid for 3 weeks followed by 20
mg od (n=870) [12]. bid, twice daily; od, once daily. Reproduced from Mueck W, Lensing AW, Agnelli G et al. Rivaroxaban: population pharmacokinetic
analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
Clin Pharmacokinet 2011; 50:675–686 with permission from Adis (© Springer International Publishing AG 2011. All rights reserved).
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until an international normalised ratio (INR) of 2–3 was
achieved. The dual-drug regimen with dabigatran was
shown to be as effective as standard therapy, with a
similar safety profile. Two further studies have shown
dabigatran 150 mg bid to be effective for the long-term
treatment of VTE, although the results of one study
showed that dabigatran significantly increased the inci-
dence of ACS compared with warfarin [71,72].
Apixaban is being evaluated for VTE treatment in two
phase III clinical trials. The AMPLIFY study will com-
pare apixaban 10 mg bid for 7 days followed by 5 mg
bid with standard therapy for the treatment of acute
VTE (www.clinicaltrials.gov; NCT00643201). AMPLIFY-
EXT evaluated apixaban 2.5 mg bid or 5 mg bid versus
placebo for 12 months after initial treatment of VTE.
The recently published results demonstrated a signifi-
cant reduction in recurrent VTE with apixaban without
an increase in major bleeding [73].
Stroke prevention in patients with non-valvular atrial
fibrillation
Partially as a result of an ageing population, AF is now the
most commonly occurring heart arrhythmia [74,75] and is
a major risk factor for stroke [74]. The phase III ROCKET
AF study showed that rivaroxaban (20 mg od) was non-
inferior to dose-adjusted VKA therapy in patients with AF
for the prevention of stroke and systemic embolism, with
similar rates of bleeding [76]. In the secondary efficacy ana-
lysis in the as-treated safety population, rivaroxaban dem-
onstrated superiority compared with warfarin. Importantly,rates of intracranial haemorrhage were significantly lower
with rivaroxaban, and the incidences of myocardial infarc-
tion, vascular death or all-cause mortality were numerically
lower [76]. Observed rivaroxaban plasma concentrations
(mean, 5/95 percentiles) are shown in Table 2. A population
PK model for rivaroxaban in patients with AF was
constructed based on data from the DVT treatment stud-
ies, taking into account the fact that AF populations are
typically older than those undergoing orthopaedic surgery
or requiring treatment for VTE [12]. A virtual population
of 1000 elderly patients with AF was simulated; results indi-
cated that the average Cmax and AUC of rivaroxaban in pa-
tients with AF could be expected to be slightly higher (7.4%
for Cmax; 15.3% for AUC) than values for patients with
DVT [12]. Renal impairment was expected to lead to in-
creased exposure [12]. These predictions were subsequently
confirmed in a population PK analysis of the ROCKET AF
dataset, which included data from 161 individuals. Appar-
ent clearance and volume of distribution at steady state
were estimated to be approximately 6 l/h and 80 litres,
respectively, with moderate interindividual variability
(Table 3). PK parameters for patients with moderate
renal impairment given rivaroxaban 15 mg od were gen-
erally similar to those estimated for patients with either
no or mild renal impairment who received rivaroxaban
20 mg od. Ratios of the means of Cmax and AUC for
time 0 to 24 hours (AUC0–24) were 0.88 and 0.91, re-
spectively, for patients with moderate renal impairment
compared with those with mild impairment or normal
renal function, and the distributions overlapped consid-
erably, supporting the use of a reduced rivaroxaban
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ment [I Girgis. Unpublished data]. In addition, model-
ling work supported the use of a lower rivaroxaban dose
in Japanese patients with AF [77,78], and in a phase III
randomised study (J-ROCKET AF) a 15 mg od dose was
found to be non-inferior to warfarin (hazard ratio 1.11;
95% confidence interval 0.87–1.42) for the prevention
of stroke and systemic embolism [79].
Dabigatran was evaluated for the prevention of stroke
in patients with AF in the phase III RE-LY study. In
RE-LY, dabigatran 150 mg bid significantly reduced the
risk of stroke or systemic embolism compared with war-
farin, with a similar rate of major bleeding, whereas the
110 mg bid dabigatran dose had similar efficacy to war-
farin and with significantly lower rates of major bleeding
[80,81]. Data from phase I and II studies of dabigatran
in healthy subjects (n = 128) and patients undergoing
orthopaedic surgery or with AF (n = 2252) were used to
construct a population PK model for dabigatran, which
was then validated by comparison with PK data collected
in RELY [82]. Given the high renal clearance of
dabigatran, CrCl was built into the baseline assumptions
for the model, and PD data were evaluated with the use
of activated partial thromboplastin time (aPTT) assays.
For the development of a PK model for dabigatran, a
dataset was collated from 80 healthy volunteers (44% of
whom had some level of renal impairment) and 1965 pa-
tients [82]. For both patients and healthy controls, the PK
of dabigatran was best described by a two-compartment
model and there was a linear correlation between clear-
ance and renal function. Age, gender and therapeutic indi-
cation (AF or orthopaedic surgery) influenced clearance,
and body weight influenced volume of distribution [82].
The values predicted by the model agreed well with those
observed in RE-LY, and there was a linear correlation be-
tween dabigatran exposure and aPTT prolongation. Using
the data to simulate plasma concentration–time profiles
at steady state for a typical male patient with AF (age
68 years, weight 80 kg, CrCl 87 ml/min) controlling for a
variety of covariates, the effect remained within the overall
variability for the average patient with AF, with the excep-
tion of renal impairment, which led to increases in expos-
ure of 40% for a CrCl of 50 ml/min and 90% with a CrCl
of 30 ml/min. There was less peak-to-trough fluctuation
with dabigatran dosing at 150 mg bid than for 300 mg od
[82]. Further simulations of patients with moderate and
severe renal impairment indicated that, compared with
patients with moderate renal impairment (CrCl >30–
49 ml/min) given dabigatran 150 mg bid, those with se-
vere impairment (CrCl 15–30 ml/min) had a 35% higher
average Cmax with dabigatran 150 mg od and a 42% lower
average Ctrough with a dabigatran 75 mg od dose.
Dabigatran 75 mg bid resulted in a reasonable matching
of exposures [83].Secondary prevention of major cardiovascular events in
patients with acute coronary syndrome
In the recent phase III ATLAS ACS 2 TIMI 51 trial,
rivaroxaban 2.5 mg bid or 5 mg bid was shown to sig-
nificantly reduce the incidence of death, myocardial in-
farction or stroke compared with placebo when added to
standard dual anti-platelet therapy (ASA plus either
clopidogrel or ticlopidine) in patients with ACS [84].
Using data from the preceding phase II study, ATLAS ACS
TIMI 46 [85], a population PK model was constructed to
characterise the parameters of rivaroxaban in this popula-
tion and model the effects of demographic variations on
rivaroxaban PK [86]. Data from 2290 patients were used
and the observed rivaroxaban plasma concentrations
(mean, 5/95 percentiles) are shown in Table 2. As for the
models in other patient populations, rivaroxaban PK was
described by an oral one-compartment model. Apparent
clearance and volume of distribution were approximately
6.5 l/h and 58 litres, respectively, with low-to-moderate
interindividual variability. Variations in renal function, age
and body weight on exposure were consistent with previ-
ous findings and PK parameters were similar to those esti-
mated for other patient populations (Table 3) [86].
The phase III APPRAISE-2 trial of apixaban demon-
strated that in high-risk patients after ACS the addition
of apixaban 5 mg bid to antiplatelet therapy increased
rates of major bleeding without significantly reducing
the rates of recurrent ischaemic events [87]. Dabigatran
is not being investigated in phase III studies of patients
with ACS.
Laboratory monitoring of novel oral
anticoagulants
Because novel OACs competitively and directly inhibit
specific factors of the coagulation cascade, their concen-
tration–time profiles directly determine the time course of
inhibition (taking into consideration fluctuations with ab-
sorption and elimination processes associated with oral
dosing). This is in contrast to warfarin, which works indir-
ectly by inhibiting components necessary for the synthesis
of blood coagulation factors; therefore, inhibition by war-
farin is determined by the half-life of synthesis. The pre-
dictable PK and PD profiles of rivaroxaban and other
novel OACs mean that routine coagulation monitoring is
not normally required [88]. However, in cases where an
emergency intervention requires immediate assessment of
anticoagulation, such as prior to urgent surgery, it may be
useful or essential to be able to measure the anticoagulant
effect of a novel OAC. Available tests can be divided into
assays that measure general clot formation and those that
directly quantify inhibition of a specific clotting factor.
Owing to their modes of action, novel OACs affect some
of these assays in different ways and an understanding of
this is key to correctly interpreting results.
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The most commonly available clot-based assays include
the PT, dilute PT, aPTT, ecarin clotting time (ECT),
HepTest and prothrombinase-induced clotting time
(PiCT) [89]. Each of these tests measures the time taken
for a plasma sample to form a clot after the addition of
calcium and an activator in the presence of the anti-
coagulant to be monitored. This means that they are not
specific to any particular anticoagulant. The effects of
rivaroxaban, dabigatran and apixaban on these tests are
summarised in Table 4.
PT measures the time for plasma to clot after the
addition of calcium and thromboplastin. The results are
always given in seconds. Rivaroxaban prolongs PT in a
dose-dependent manner but the extent of prolongation
depends on the thromboplastin reagent used [90,91]. A
multicentre study that evaluated the interlaboratory vari-
ability of PT measurements with rivaroxaban found that
the use of local reagents led to greater variability than
when all laboratories used a standardised Neoplastine CI
Plus test (Diagnostica Stago, Asnières-sur-Seine, France),
which had a higher sensitivity for rivaroxaban than many
other PT assays [92]. Another group has also recently
reported reproducible results with a calcium chloride-
modified PT assay [93]. The variation in the sensitivity
of different thromboplastin reagents is overcome for
VKA monitoring by conversion to the INR, but this is
specific to VKAs and cannot be used with rivaroxaban
or the other novel OACs [91].
Even with standardisation, there are a number of other
limitations of PT when applied to novel OACs [89,90].
The presence of concomitant systemic conditions, such as
hepatic impairment, sepsis or vitamin K deficiency, can
lead to a prolongation of PT. The PT is dependent on fac-
tors of the extrinsic coagulation pathway other than Factor
Xa and it is not specific to any agent. Furthermore, the
short half-life of, for example, rivaroxaban (5–13 hours)
led to transient PT results, whereas for warfarin (half-life
36–42 hours) less variability can be expected. In addition,
disappearance from the plasma of a Factor Xa inhibiting
agent does not always correlate with a return to normal
Factor Xa levels. Finally, PT reagents are insensitive at low
concentrations of rivaroxaban [89,90] and are not able to
accurately measure the Ctrough levels predicted for
rivaroxaban in PK models: Ctrough levels were in the range
9–32 ng/ml (Table 3) but Neoplastine Plus can only meas-
ure plasma levels down to approximately 50 ng/ml, mean-
ing that a PT reading taken around the time of Ctrough will
likely provide a false negative result [89]. These limitations
also apply to dilute PT assays. Nevertheless, if used in an
emergency and in the absence of any other available test,
Neoplastine Plus (with results expressed in seconds) is the
recommended agent for assessing the anticoagulant effect
of rivaroxaban [3].The aPTT test is performed in the absence of a tissue
factor and, therefore, measures the overall function of the
intrinsic coagulation pathway. Traditionally performed to
monitor coagulation with unfractionated heparin, aPTT is
performed by adding a contact activator (e.g. celite, ellagic
acid, kaolin or silica) and cephalins to citrated plasma
[89]. Calcium is added after a preincubation period and
the clotting time is then measured. When using aPTT to
assess rivaroxaban and apixaban, the test was less sensitive
than PT, and results with dabigatran were non-linear at
higher doses [89,90]. A recent study that tested a range of
clotting assays with dabigatran suggested that aPTT could
be used as a screening test for the risk of overdose but not
for quantitative measurement of dabigatran [94].
HepTest is a clot-based anti-Factor Xa assay, in which a
plasma sample is preincubated with bovine Factor Xa be-
fore addition of calcium chloride and thromboplastin.
Rivaroxaban prolongs HepTest clotting time, although a
shortened incubation time must be used with low concen-
trations to ensure a linear dose–response [91]. In contrast,
ECT measures thrombin clotting using a derivative of
snake venom to generate a prothrombin intermediate, and
is thus likely to be more appropriate for monitoring
dabigatran activity. Indeed, dabigatran prolongs ECT in a
dose-dependent manner and can be calibrated to
dabigatran concentrations [95]. The thrombin generation
test is capable of assessing each phase of thrombin gener-
ation but may lack sensitivity [89], whereas another assay,
Hemoclot, has been reported to have high sensitivity, good
reproducibility and a linear dose correlation with
dabigatran [90,94]. The PiCT test, which uses Factor Xa,
phospholipids and a Factor V activator, is affected by both
Factor Xa and thrombin inhibitors. Rivaroxaban and
dabigatran prolong PiCT, although incubation should be
avoided with rivaroxaban and human, rather than bovine,
Factor Xa must be used [89]. However, as with many of the
other tests described, a lack of sensitivity at low concentra-
tions and variation between tests limit their usefulness for
assessing novel OACs [89].
Chromogenic assays
Chromogenic assays measure the change in absorbance
when a chromophore-tagged substrate of a specific clot-
ting factor is cleaved by the coagulation factor to be mea-
sured, a process that is inhibited by the presence of the
anticoagulant [89]. Such assays are more specific than
clot-based assays and have proved suitable for quantitative
measurement of rivaroxaban exposure with dose-
dependent results covering both the expected Cmax and
Ctrough levels after therapeutic doses. Nevertheless, appro-
priate calibration over a wide range of plasma concentra-
tions is required to create a standard reference dose–
response curve [89,90]. A recent ex vivo study evaluated
the accuracy of three anti-Factor Xa chromogenic assays
Table 4 Comparison and suitability of laboratory assays for monitoring novel oral anticoagulants [89,90]
Agent PT Dilute
PT
aPTT ECT HepTest PiCT Chromogenic
assays
Preferred assay Assays that may
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samples from healthy subjects and patients [96]. Assays
that did and did not include exogenous antithrombin, with
two different concentration calibration sets for each, were
investigated. All assays showed a linear relationship be-
tween actual rivaroxaban concentrations and the optical
density of the chromogenic assays. However, although the
non-antithrombin assays were able to provide accurate re-
sults over a wide range of rivaroxaban concentrations, the
assay that contained exogenous antithrombin provided
falsely elevated results, suggesting that it is unsuitable for
use with rivaroxaban [96].
A recent field trial investigated the inter-laboratory
viability of the measurement of rivaroxaban plasma con-
centrations with anti-Factor Xa chromogenic assays. The
study was conducted in 24 laboratories in Europe and
North America using standardised rivaroxaban calibra-
tors and plasma control samples [97]. Each centre used
both the centrally provided modified STAW RotachromW
assay (Diagnostica Stago) and local Factor Xa reagents
to perform tests on a variety of sample concentrations.
Using the centrally provided assay, a lower inter-
laboratory variation was found compared with when
local reagents were employed, with the greatest differ-
ence found at lower concentrations of rivaroxaban. This
study suggests that, using standard calibrators and con-
trols, a range of rivaroxaban plasma concentrations (20–
660 ng/ml), which covers the expected rivaroxaban
plasma levels after therapeutic doses, could be measured
using the chromogenic anti-Factor Xa assay STA
Rotachrom [97]. This assay could provide a more sensi-
tive and specific alternative to the previously described
PT method for the measurement of rivaroxaban plasma
concentrations. The STA Rotachrom assay and two
other chromogenic assays, Biophen DiXaIW (Hyphen
Biomed) and TechnochromW anti-Xa (Technoclone),
have received European authorisation for commercial
distribution. STA Rotachrom has been identified as the
preferred assay for measuring the activity of apixaban
[5]. Chromogenic assays to measure dabigatran are cur-
rently in development.
Discussion
Of the three currently licensed novel OACs, the PK and
PD profile of rivaroxaban is arguably the most fully elu-
cidated. Observations in phase I and phase II studies
have shown that rivaroxaban has predictable, dose-
proportional PK with an anticoagulant effect that also
increases in a linear fashion with increasing plasma con-
centration; importantly, this profile is largely consistent
in the presence or absence of demographic variations
[22]. Although characterisation of PK in healthy subjects
is important, it is vital to understand how a drug is likely
to behave in actual patient populations. The use ofpopulation PK modelling is an invaluable tool for achiev-
ing full PK and PD characterisation. There is now a sub-
stantial body of patient modelling data published for
rivaroxaban and dabigatran, although this is currently
lacking for apixaban. One advantage of PK modelling is
that it can be used to simulate ‘extreme’ scenarios, such
as those that present in patients who are elderly, have
renal or hepatic impairment, or who are obese. The
models described herein show that, for the most part,
the PK and PD profiles of rivaroxaban and dabigatran
remain within acceptable boundaries for most individual
patients, supporting the use of fixed dosing regimens
[11,12,52,57,82]. Overall, both agents exhibit only mod-
erate PK/PD variability, which contrasts with the unpre-
dictable interindividual variations seen with warfarin
that necessitate routine coagulation monitoring.
The other novel OACs also exhibit similarly predict-
able profiles, but some comparative PK properties differ
in ways that may be important to consider in a given
clinical situation. For example, the high renal clearance
of dabigatran (80%) means that it is not considered suit-
able in the EU for patients with severe renal insuffi-
ciency (CrCl 15– < 30 ml/min) [6], although it can be
used for the prevention of stroke in severely renally im-
paired patients with AF in the US (at a reduced 75 mg
od dose) [8]. Rivaroxaban and apixaban, which are elimi-
nated in greater proportions via other non-renal routes,
may be used with caution in the relevant licensed indica-
tion in such patients [3,5]. Equally, the drug interaction
profile of each agent may be an important consideration if
a patient is taking concomitant medications. Rivaroxaban
should not be used in conjunction with strong inhibitors of
both CYP3A4 and Pgp, such as azole-antimycotics (e.g. ke-
toconazole, itraconazole, voriconazole and posaconazole) or
HIV protease inhibitors (e.g. ritonavir) because competi-
tive elimination with rivaroxaban will increase exposure to
the latter to a clinically relevant degree [3,35]. However,
comedication with strong inhibitors of one of these path-
ways only, or moderate inhibitors of both, may be consid-
ered with caution. In contrast, dabigatran is not metabolised
via CYP3A4 pathways but should not be co-administered
with potent P-gp inhibitors (e.g. amiodarone) [6], and
apixaban should not be given in conjunction with strong
CYP3A4 inhibitors but is not affected by competition for
P-gp transport [5].
An important observation derived from population PK
modelling is the effect of renal clearance and age on the
PK/PD profiles of rivaroxaban and dabigatran. These
two parameters are often linked because renal efficiency
decreases with advancing age. Results of PK modelling
with dabigatran led to recommendations for a reduced
dose of 150 mg od to be used for VTE prevention in pa-
tients with moderate renal impairment (CrCl 30–49 ml/
min) [6,83]. Rivaroxaban modelling confirmed that no
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49 ml/min (moderate or severe renal impairment) re-
ceiving the 10 mg dose approved for VTE prevention
after elective hip and knee replacement surgery. For the
treatment of DVT in patients with CrCl 15–49 ml/min,
rivaroxaban PK modelling supported the recommended
15 mg bid dose for the acute phase (first 21 days) of
therapy and a reduced dose of rivaroxaban 15 mg od for
the extended treatment phase (post-day 21). For the pre-
vention of stroke and systemic embolism in patients
with non-valvular AF and CrCl <50 ml/min, the reduced
dose of rivaroxaban 15 mg od was supported by phase
III trial data (CrCl 30–49 ml/min; moderate renal im-
pairment) and modelling (CrCl 15– < 30 ml/min; severe
renal impairment) [3,76]. Given that data are limited,
rivaroxaban should be used with caution in patients with
CrCl 15– < 30 ml/min in all settings [3].
Although not routinely required, laboratory testing of
anticoagulant activity may sometimes be necessary when
employing novel OACs. Because of the PK/PD properties
of these agents, few clot-based assays are appropriate for
this task, and in general there is a lack of standardised cali-
bration and methodology for conducting these tests with
the novel OACs [90,95]. This contrasts to the case with
warfarin, for which cumulative years of experience have
led to a standardised calibration of PT test results using
the INR. At clinically relevant plasma concentrations of
rivaroxaban, the effect on PT prolongation is small and
short-lived, and the test has a low sensitivity for all novel
OACs [90,95]. However, the advantage of PT is that it is a
standard test that is available and can be performed rap-
idly in most clinical laboratories worldwide [92]. Chromo-
genic assays that respond to specific coagulation factors
are now available and can provide specific, sensitive and
accurate quantitative measurement of rivaroxaban expos-
ure within the expected range of plasma concentration
seen with therapeutic doses [90,95].
For this reason, approved chromogenic assays should
be regarded as the gold standard for measuring
rivaroxaban plasma levels under the unusual circum-
stances where this may be required. It is important to
note that, regardless of the assay used, the result will
provide an indication of drug plasma levels but not a
direct measurement of anticoagulation. Therefore,
chromogenic assays should only be used to establish
the presence or absence of the drug in plasma; the po-
tential influence of the time of drug administration
should be taken into consideration when interpreting
the results. This differs from INR monitoring for VKAs
where a safe and effective range is targeted and the
INR results ultimately drive treatment decisions. With
the anticipated increase in the use of novel OACs, la-
boratories should familiarise themselves with chromo-
genic assays and how the results should be interpreted.Conclusions
Rivaroxaban and dabigatran (and apixaban based on such
data as have been published) have predictable PK and PD
properties allowing for fixed oral dosing regimens to be
followed regardless of demographic variations without the
need for routine coagulation monitoring in most cases. The
relatively short half-life of these drugs and the direct correl-
ation between concentration–time profile and inhibition
are advantages for fast offset of action when treatment is
stopped. In circumstances where the measurement of
plasma concentration is required, the use of standardised
calibrators and controls is essential to obtaining accurate
data – this appears possible with anti-Factor Xa chromo-
genic assays for rivaroxaban and apixaban, and HemoClot,
ECT or aPTT for dabigatran. However, it is important that
the results of any of these assays are interpreted within the
context of the time of drug administration.
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